
THAT WHICH IS CLAIMED IS:

1. A compound of Formula I:



I,

or a pharmaceutically acceptable salt thereof,

wherein:

n is 0 or 1;

p is 1 or 2;

Ring A is a saturated 5- or 6-membered monocyclic or bicyclic carbocyclyl;

Ring B is phenyl, 6-membered heteroaryl, or 6-membered saturated or partially saturated cycloalkyl, wherein the heteroaryl contains one or two heteroatoms;

R^3, in each instance, is independently selected from the group consisting of C_1-C_6 alkyl, halo-C_1-C_6 alkyl, hydroxy, C_1-C_6 alkoxy, halo-C_1-C_6 alkoxy, halo, and cyano;

G is N or CR^G, wherein R^G is selected from the group consisting of hydrogen, C_1-C_6 alkyl, and halo-C_1-C_6 alkyl;

R^{N1} is selected from the group consisting of hydrogen, C_1-C_6 alkyl, halo-C_1-C_6 alkyl, and C_3-C_5 cycloalkyl;

R^2 is selected from the group consisting of C_1-C_6 alkyl, halo, and halo-C_1-C_6 alkyl;

y is 1 or 2;

m is 0, 1, 2, or 3;

X is O or NR^H;

R^H is selected from the group consisting of hydrogen, C_1-C_6 alkyl, halo-C_1-C_6 alkyl, C_3-C_5 cycloalkyl, hydroxy-C_1-C_6 alkyl, and C_1-C_6 alkoxy-C_1-C_6 alkyl;


and,

R^1 in each instance, is selected from the group consisting of C_1-C_6 alkyl, halo-C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy, NR^ER^F, halo-C_1-C_6 alkoxy, hydroxy-C_1-C_6 alkyl, and C_1-C_6 alkoxy-C_1-C_6 alkyl; or, two R^1 groups come together to form a -CH_2- or -CH_2CH_2- bridge;

R^E and R^F are each independently selected from the group consisting of hydrogen, C_1-C_6 alkyl, halo-C_1-C_6 alkyl, C_3-C_5 cycloalkyl, hydroxy-C_1-C_6 alkyl, and C_1-C_6 alkoxy-C_1-C_6 alkyl.

2. The compound of claim 1, wherein Ring A is selected from the group consisting of cyclopentyl, cyclohexyl, and bicyclo[3.1.0]hexanyl.


3. The compound of claim 2, wherein Ring A is cyclopentyl, and having the formula:




.

4. The compound of claim 1, wherein Ring B is selected from the group consisting of cyclohexyl, phenyl, pyridinyl, pyrimidinyl, and pyrazinyl.

5. The compound of claim 2, which is of formula:




or



.

6. The compound of claim 1, wherein the compound is of Formula Ia or Ia’:




Ia,

or a pharmaceutically acceptable salt thereof,

wherein,


Y^1, Y^2, Y^3, Y^4, and Y^5 are each independently N, C or CH, provided that only one or two of Y^1, Y^2, Y^3, Y^4, and Y^5 can be N; or,



Ia’,

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1, wherein the compound is of Formula Ib:



Ib,

or a pharmaceutically acceptable salt thereof,

wherein:

Y^1, Y^2, Y^3, Y^4, and Y^5 are each independently N, C or CH, provided that only one or two of Y^1, Y^2, Y^3, Y^4, and Y^5 can be N; and

u is 1 or 2.

8. The compound of claim 6, wherein

(i) Y^1 is CH, Y^2 is CR^3, Y^3 is CH, Y^4 is N, and Y^5 is CH;

(ii) Y^1 is CH, Y^2 is N, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;

(iii) Y^1 is N, Y^2 is CR^3, Y^3 is CH, Y^4 is CH, and Y^5 is CH;

(iv) Y^1 is CH, Y^2 is CR^3, Y^3 is CH, Y^4 is CH, and Y^5 is CH;

(v) Y^1 is CH, Y^2 is CR^3, Y^3 is CH, Y^4 is CH, and Y^5 is N;

(vi) Y^1 is CH, Y^2 is N, Y^3 is CR^3, Y^4 is N, and Y^5 is CH;

(vii) Y^1 is N, Y^2 is CR^3, Y^3 is N, Y^4 is CH, and Y^5 is CH;

(viii) Y^1 is CH, Y^2 is CR^3, Y^3 is N, Y^4 is CH, and Y^5 is N;

(ix) Y^1 is N, Y^2 is CR^3, Y^3 is CH, Y^4 is N, and Y^5 is CH;

(x) Y^1 is CH, Y^2 is CR^3, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;

(xi) Y^1 is CH, Y^2 is N, Y^3 is CR^3, Y^4 is CR^3, and Y^5 is CH;

(xii) Y^1 is CH, Y^2 is CR^3, Y^3 is N, Y^4 is CH, and Y^5 is CH;

(xiii) Y^1 is CH, Y^2 is CH, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;

(xiv) Y^1 is N, Y^2 is CH, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH; or,

(xv) Y^1 is CR^3, Y^2 is CH, Y^3 is CH, Y^4 is CH, and Y^5 is CH.

9. The compound of claim 7, wherein

(i) Y^1 is CH, Y^2 is CR^3, Y^3 is CH, Y^4 is N, and Y^5 is CH;

(ii) Y^1 is CH, Y^2 is N, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;

(iii) Y^1 is N, Y^2 is CR^3, Y^3 is CH, Y^4 is CH, and Y^5 is CH;

(iv) Y^1 is CH, Y^2 is CR^3, Y^3 is CH, Y^4 is CH, and Y^5 is CH;

(v) Y^1 is CH, Y^2 is CR^3, Y^3 is CH, Y^4 is CH, and Y^5 is N;

(vi) Y^1 is CH, Y^2 is N, Y^3 is CR^3, Y^4 is N, and Y^5 is CH;

(vii) Y^1 is N, Y^2 is CR^3, Y^3 is N, Y^4 is CH, and Y^5 is CH;

(viii) Y^1 is CH, Y^2 is CR^3, Y^3 is N, Y^4 is CH, and Y^5 is N;

(ix) Y^1 is N, Y^2 is CR^3, Y^3 is CH, Y^4 is N, and Y^5 is CH;

(x) Y^1 is CH, Y^2 is CR^3, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;

(xi) Y^1 is CH, Y^2 is N, Y^3 is CR^3, Y^4 is CR^3, and Y^5 is CH;


(xii) Y^1 is CH, Y^2 is CR^3, Y^3 is N, Y^4 is CH, and Y^5 is CH;

(xiii) Y^1 is CH, Y^2 is CH, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;

(xiv) Y^1 is N, Y^2 is CH, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH; or,

(xv) Y^1 is CR^3, Y^2 is CH, Y^3 is CH, Y^4 is CH, and Y^5 is CH.

10. The compound of claim 1, wherein the compound is of Formula Ib':




Ib',


or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1, wherein G is N.

12. The compound of claim 11, having the formula:



or




.


13. The compound of claim 12, wherein Ring B is cyclohexyl, phenyl, pyridinyl, pyrimidinyl, or pyrazinyl.

14. The compound of claim 1, wherein G is CH.

15. The compound of claim 14, having the formula:







or






.

16. The compound of claim 1, wherein X is O.




17. The compound of claim 16, wherein X, R^1, m, and y in the ring form:


,
, 
, 
, 
,



, 
, or 
.

18. The compound of claim 1, wherein X is NR^H.


19. The compound of claim 18, wherein X, R^1, m, and y in the ring form:


, 
, or 
.

20. The compound of claim 1, wherein the compound is of Formula Ia1 or 1b1:



Ia1



Ib1,

or a pharmaceutically acceptable salt thereof,

wherein:

u is 1 or 2;

m is 0, 1, or 2;

Y^1, Y^2, Y^3, Y^4, and Y^5 are each independently CH, CR^3, or N, provided that only one or two of Y^1, Y^2, Y^3, Y^4, and Y^5 can be N;

G is N or CH; and

R^1, if present, in each instance is independently selected from the group consisting of C_1-C_6 alkyl and halo-C_1-C_6 alkyl; or wherein two R^1 groups come together to form a -CH_2- or -CH_2CH_2- bridge.

21. The compound of claim 20, wherein:

Y^1 is CH, Y^2 is CR^3, Y^3 is CH, Y^4 is N, and Y^5 is CH;

Y^1 is CH, Y^2 is N, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;

Y^1 is N, Y^2 is CR^3, Y^3 is CH, Y^4 is CH, and Y^5 is CH;

Y^1 is CH, Y^2 is CR^3, Y^3 is CH, Y^4 is CH, and Y^5 is CH;

Y^1 is CH, Y^2 is CR^3, Y^3 is CH, Y^4 is CH, and Y^5 is N;

Y^1 is CH, Y^2 is N, Y^3 is CR^3, Y^4 is N, and Y^5 is CH;

Y^1 is N, Y^2 is CR^3, Y^3 is N, Y^4 is CH, and Y^5 is CH;

Y^1 is CH, Y^2 is CR^3, Y^3 is N, Y^4 is CH, and Y^5 is N;

Y^1 is N, Y^2 is CR^3, Y^3 is CH, Y^4 is N, and Y^5 is CH;

Y^1 is CH, Y^2 is CR^3, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;

Y^1 is CH, Y^2 is N, Y^3 is CR^3, Y^4 is CR^3, and Y^5 is CH;

Y^1 is CH, Y^2 is CR^3, Y^3 is N, Y^4 is CH, and Y^5 is CH;


Y^1 is CH, Y^2 is CH, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;

Y^1 is N, Y^2 is CH, Y^3 is CR^3, Y^4 is CH, and Y^5 is CH;


or,

Y^1 is CR^3, Y^2 is CH, Y^3 is CH, Y^4 is CH, and Y^5 is CH.

22. The compound of claim 1, wherein the compound is of Formula Ia2 or 1b2:



Ia2



Ib2

or a pharmaceutically acceptable salt thereof,


wherein:

u is 1 or 2;

Y^1, Y^2, Y^3, Y^4, and Y^5 are each independently CH, CR^3, or N, provided that only one or two of Y^1, Y^2, Y^3, Y^4, and Y^5 can be N; and

G is N or CH.


23. The compound of claim 1, wherein Ring A is a bicyclo[3.1.0]hexanyl having the following structure:



,

wherein * indicates attachment to the N-atom and # indicates attachment to C-atom on the triazole or pyrazole moiety.

24. The compound of any one of claims 1, 3, 5, 7, 10, 11, 15, 20, or 22, wherein Ring A is a cyclopentyl having the following structure:



.

25. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from Table 1.

26. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

27. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disorder in a subject in need thereof.

28. The use of claim 27, wherein the disorder is a myelin-related disorder, optionally wherein the myelin-related disorder is multiple sclerosis (MS), neuromyelitis optica (NMO), optic neuritis, pediatric leukodystrophy, neonatal white matter injury, age-related dementia, schizophrenia, progressive multifocal leukoencephalopathy (PML), encephalomyelitis (EPL), central pontine myelolysis (CPM), adrenoleukodystrophy, Alexander's disease, Pelizaeus Merzbacher disease (PMD), Vanishing White Matter Disease, Wallerian Degeneration, transverse myelitis, amylotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, Parkinson's disease, spinal cord injury, traumatic brain injury, post radiation injury, neurologic complications of chemotherapy, stroke, acute ischemic optic neuropathy, vitamin E deficiency, isolated vitamin E deficiency syndrome, Bassen-Kornzweig syndrome,

Marchiafava-Bignami syndrome, metachromatic leukodystrophy, trigeminal neuralgia, acute disseminated encephalitis, Guillian-Barre syndrome, Charcot-Marie-Tooth disease, Bell's palsy, or radiation-induced demyelination.

29. Use of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for promoting myelination in a subject in need thereof.

30. The use of claim 29, wherein the subject has a myelin-related disorder.